Table 2.
Evaluation of Liver and Body Weight, Liver/Body Weight Ratio, Serum and Bile Sct Levels, and Levels of TGF-β1 in Serum and Cholangiocyte Supernatant
| Treatment | Normal WT | Normal Sct−/− | Normal SR−/− | Normal Sct−/−/SR−/− | BDL WT | BDL Sct−/− | BDL SR−/− | BDL Sct−/−/SR−/− |
|---|---|---|---|---|---|---|---|---|
| Liver weight, g (n) | 1.4 ± 0.04 (52) | 1.6 ± 0.05 (52) | 1.8 ± 0.06 (51) | 1.8 ± 0.07 (52) | 1.7 ± 0.07 (50) | 1.7 ± 0.06 (50) | 1.8 ± 0.09 (29) | 1.8 ± 0.06 (37) |
| Body weight, g (n) | 24.5 ± 0.4 (52) | 27.4 ± 0.7 (52) | 32.0 ± 1.0 (51) | 32.3 ± 0.9 (52) | 21.1 ± 0.3 (50) | 23.0 ± 0.5 (50) | 25.3 ± 0.9 (29) | 25.7 ± 0.6 (37) |
| Liver/body weight, % (n) | 5.9 ± 0.1 (52) | 5.9 ± 0.1 (52) | 5.7 ± 0.1 (51) | 5.6 ± 0.1 (52) | 8.0 ± 0.3 (50)∗ | 7.3 ± 0.2 (50)† | 7.0 ± 0.3 (29)† | 7.0 ± 0.2 (37)† |
| Sct, ng/mL (n) | ||||||||
| Serum | 0.13 ± 0.02 (3) | 0.14 ± 0.03 (3) | 0.13 ± 0.01 (3) | 0.24 ± 0.02 (3) | 67.54 ± 3.79 (3)∗ | 0.73 ± 1.56 (3)† | 0.42 ± 0.04 (3)† | 0.40 ± 0.02 (3)† |
| Bile | 0.79 ± 0.08 (3) | 1.18 ± 0.18 (3) | <0.01 (3) | 0.51 ± 0.02 (3) | 21.16 ± 2.97 (3)∗ | 3.90 ± 1.14 (3)† | 5.01 ± 1.74 (3)† | 4.95 ± 0.59 (3)† |
| TGF-β1, pg/mL (n) | ||||||||
| Serum | 148.3 ± 4.6 (3) | 181.5 ±0 .34.6 (3) | 128.4 ± 3.9 (3) | 132.6 ± 3.9 (3) | 3252 ± 564 (3)∗ | 231.2 ± 11.0 (3)† | 86.8 ± 1.8 (3)† | 80.7 ± 1.0 (3)† |
| Cholangiocyte supernatant | 37.8 ± 0.6 (3) | 37.7 ± 0.5 (3) | 37.2 ± 0.2 (3) | 37.7 ± 0.5 (3) | 145.4 ± 9.7 (6)∗ | 37.8 ± 0.2 (3)† | 37.9 ± 0.5 (3)† | 37.5 ± 1.2 (3)† |
BDL, bile duct ligated; TGF-β1, transforming growth factor-β1; WT, wild type.
∗
P < 0.05 versus normal WT mice.
†
P < 0.05 versus BDL WT mice.